french eclips™ efficacy and safety investigation

Conditions: Intracranial Aneurysm

Summary: the objective of this study is to demonstrate the safety and efficacy of the eclips™ products for the treatment of bifurcation aneurysms.

this study is a multicentre, open label, historically controlled, single-arm safety and efficacy study of the eclips™ products in the management of bifurcated intracranial aneurysms at basilar tip and carotid terminus. patients with basilar tip and carotid terminus aneurysms are not considered suitable for surgical treatment by the neurovascular community because of the poor outcome in these localizations. patients included in the study will have saccular intracranial aneurysms that arise at or adjacent to a bifurcation, having a neck length of ≥ 4mm or have a dome:neck ratio \<2. efficacy will be measured as the proportion of aneurysms achieving complete occlusion (raymond-roy 1) at 12 months, while safety will be measured as the proportion of patients without a major stroke or non-accidental death within 30 days (procedural) and without a major ipsilateral stroke or neurological death between 31 days and 12 months. additional endpoints will be evaluated and data collected to assess safety and collect information on the eclips™ family of products.

Eligibility criteria:
inclusion criteria: 1. patient whose age is greater than 18 years old 2. patient with an unruptured or previously ruptured (at least 1 month from date of rupture and with partial occlusion of the dome of the aneurysm by endovascular techniques or by open neurosurgery, and in stable neurological condition-wfns i and ii with a good recovery to at least to mrs 0-2) saccular, intracranial aneurysm or recurrent aneurysm, which arises at a bifurcation of basilar tip or carotid terminus with a minimal diameter of 5mm and a maximal diameter \ 4mm or dome:neck ratio \<2, branch artery diameters in the range of 2.0mm to 3.25mm 3. patient aneurysm arises at a bifurcation artery with at least one of the two branch artery vessels having a diameter between 2.0mm and 3.25mm 4. patient understands the nature of the procedure and has the capacity to provide informed consent (including fluency in french language) 5. patient is willing to have on-site 30- day, 6-month, and 12 month follow-up evaluations as per standard clinical practice exclusion criteria: 1. patient with an aneurysm deemed to be an eligible candidate for surgical clipping by the investigator 2. patient who presents with an intracranial mass or currently undergoing radiation therapy for carcinoma of the head or neck region 3. major surgery within previous 30 days or planned in the next 120 days after enrolment 4. patient with an international normalized ratio (inr) ≥ 1.5 5. patient with serum creatinine level ≥104 µmol/l (or 2.5mg/dl) at time of enrolment 6. patient with a platelet count ˂100x103 cells/mm3 or known platelet dysfunction at time of enrolment 7. patient who has a known cardiac disorder, likely to be associated with cardio-embolic symptoms such as atrial fibrillation 8. patient with any condition that, in the opinion of the treating physician, would place the participant at a high risk of embolic stroke or with any medical co-morbidity likely to affect the outcome (e.g. pulmonary disease, uncontrolled diabetes, blood disorders) 9. patient with known allergies to nickel-titanium metal 10. patient with known allergies to aspirin, heparin, ticlopidine, clopidogrel, prasugrel or other anti-platelet or p2y12 agents or to general anesthesia 11. subject has resistance to p2y12 agents based on a validated platelet testing method (verify now, multiplate or other) 12. patient with a life threatening allergy to contrast (patients with itching or rash as a reaction to contrast can be included if properly prophylactically treated) 13. patient with inappropriate anatomy as demonstrated by angiography due to severe intracranial vessel tortuosity or stenosis, or intracranial vasospasm not responsive to medical therapy 14. patient who is currently participating in another clinical research study involving an investigational product 15. patient who has had a previous intracranial procedure associated with the target aneurysm such that access and placement of an eclips™ device would be compromised 16. stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to the treatment date 17. more than one intracranial aneurysm that requires treatment within 12 months. 18. asymptomatic extradural aneurysms requiring treatment 19. severe neurological deficit that renders the subject incapable of living independently 20. unstable neurological deficit (i.e. worsening or improvement of clinical condition in the last 30 days 21. dementia or psychiatric problem that prevents the subject from completing required follow up 22. subject had a subarachnoid haemorrhage within 1 month prior to enrolment date 23. subject has a non-treated arterio-venous malformation in the territory of the target aneurysm 24. subject has a need for long-term use of anticoagulants 25. patient who is unable to complete the required follow-up 26. inability to understand the study or history of non-compliance with medical advice 27. evidence of active infection at the time of treatment 28. patient who is pregnant or breastfeeding 29. patient who has participated in a drug study within the last 30 days 30. patient over the age of majority benefiting from legal protection (guardianship, curatorship, safeguard of justice)

Keywords: bifurcation aneurysm basilar tip carotid terminus